BREAKING NEWS: Plus Therapeutics has been selected for funding by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs (CDMRP). The award is expected to commence in Q3 2024 and will support the planned expansion of the Company’s clinical trial for pediatric brain cancer. Full Press Release: https://bit.ly/PSTV_PR #braincancer #pediatriconcology #clinicaltrials
Recent Posts
- Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
- FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
- Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
- Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
- Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation
Recent Comments